Biogen's in the doghouse


"Are they surprised? I assume it will be water of a duck's back; Pharma rarely show remorse."


Multiple Sclerosis Research: BG-12 Phase III Results: it is ...
18 Jun 2013
Objectives & Methods: To investigate the clinical efficacy of BG-12 240 mg twice daily (BID) and three times daily (TID) in MSer subgroups stratified according to baseline demographic and disease characteristics including ...
http://multiple-sclerosis-research.blogspot.com/

03 Jun 2013
PMLive. Biogen Idec says Tecfidera launch delayed in Europe. 31 May 2013 MSers in Europe who are eager to start Biogen Idec's new oral treatment Dimethyl Fumarate (Tecfidera) will now have to wait until the second half ...
22 May 2013
Biogen Idec announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of peginterferon beta-1a, a pegylated subcutaneous injectable candidate for ...
19 Apr 2013
Biogen Idec recognizes that traditional pharmacy compounding can play a useful role in personalizing treatment for an individual patient. However, this should be done by licensed pharmacists who are trained and equipped ...

Labels: , , ,